The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with XXXX in the treatment of @entity43 .

@entity1 @entity43 @entity137 @entity390 @entity417 @entity882 @entity190 @entity3003 @entity260 @entity1398
OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is an intriguing method of delivery wherein the cytotoxic agent is continuously heated and circulated throughout the peritoneum in an attempt to bolster drug efficacy. Despite HIPEC's potential, ascertaining the optimal dose without compromising @entity1 tolerability remains indeterminate. METHODS: We retrospectively evaluated 52 @entity43 @entity1 who were treated with consolidation HIPEC with @entity3003 at varying doses (e.g., AUC 6, 8 or 10) subsequent to optimal debulking surgery and the attainment of a clinical complete response to their primary chemotherapy regimen. The following @entity1 and operative characteristics were abstracted: demographics, surgery and pathology data, chemotherapy regimen, intraoperative results, @entity137 , @entity260 , length of hospital stay and survival data. RESULTS: Twelve @entity1 received HIPEC @entity3003 at an AUC 6, 15 subjects were treated with @entity3003 at an AUC 8 and 25 underwent @entity3003 at an AUC 10. There were no intraoperative complications during the administration of HIPEC; mean estimated @entity190 was 50  mL and length of hospital stay was 1.65  days. In the overall study population, 5 @entity1 developed grade 3/4 @entity417 and 33 subjects exhibited grade  <=2 @entity882 and @entity1398 . Thirteen @entity1 also developed grade  <=2 @entity390 on postoperative day 1, which was successfully addressed with anti-emetic therapy; there were no hospital readmissions. CONCLUSIONS: The results from the current evaluation suggest that consolidation hyperthermic intraperitoneal chemotherapy with @entity3003 is both feasible and reasonably tolerated, even at an AUC of 10. However, additional, randomized study of this procedure incorporating chemotherapy dose escalation with a more extensive @entity1 population is warranted.
